We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
In this systematic review, 46 articles were included, with 997 patients from 9 countries with skin manifestations related to COVID-19. Most commonly reported cutaneous manifestation included chilblain-like lesions (n=400, 40.1%), followed by maculopapular lesions (n=230, 23.1%), vesicular lesions (n=101, 10.1%), urticarial lesions (n=87, 21.8%), livedoid/necrotic lesions (n=23, 2.3%), and other/nondescript rashes/skin lesions (n=197, 19.8%). Symptoms included pain/burning (reported in at least 96 cases) and itch (reported in at least 268 cases). The prevalence of skin findings of COVID-19 varied greatly from 0.20% to 20.45%—which may suggest under-reporting.
A wide spectrum of cutaneous manifestations of COVID-19 was reported, such as chilblain-like, maculopapular, vesicular, urticarial, and livedoid/necrotic, or nondescript lesions, which may or may not be symptomatic. Increased awareness and diagnosis of skin findings related to COVID-19 is critical to help hinder community transmission in asymptomatic patients who may present only with cutaneous signs. Robust documentation and reporting cutaneous findings to the American Academy of Dermatology COVID-19 registry are highly encouraged.
– InYoung Kim, MD, PhD
This abstract is available on the publisher's site.
First described in Wuhan, China late December of 2019, Coronavirus disease 2019 (COVID-19) has emerged as a global public health emergency. Countries across the world are rapidly reporting new infections and case fatalities.1 As the COVID-19 pandemic rapidly evolves, understanding symptoms and clinical characteristics of affected persons is essential. Patients with COVID-19 often present with fever, cough and fatigue, though organ-specific symptoms have been reported. 2,3 The primary aim of this study was to systematically review published and preprint articles describing cutaneous symptoms associated with COVID-19 presentation.